EUVIMEDEUVIMED entdecken
Crossref

Preventive Effect of ZnO-Metformin Nanocomposite Against Carbon Tetrachloride-Induced Hepatotoxicity

Fatemeh Adibipour, Mahsa Salehirad, A.Wallace Hayes, Malak Hekmati, Majid Motaghinejad

Nanomedicine Research Journal · 2024-04 · 9 (2) · 155-163

DOI: 10.22034/nmrj.2024.02.004 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nanomedicine Research Journal, 2024-04. Verfasst von Fatemeh Adibipour und 4 weiteren Autor:innen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective(s): The protective effect of metformin on liver disorders has been reported . Studies have documented the hepatoprotective benefits of metformin against liver disorders, but due to its low bioavailability and untoward side effects, metformin has limited therapeutic utility. Nanotechnology has increased efficiency and reduced the side effects of several drugsMethods: A ZnO-metformin nanocomposite was synthesized. The protective effects of metformin (150 mg/kg), ZnO (10 mg/kg), and the ZnO-metformin nanocomposite (50, 100, 150 mg/kg) were compared in a CCl4-induced hepatocellular damaged mouse model. Serum liver enzymes, oxidative stress biomarkers, and histological changes in hepatocytes were evaluated.

Results

The levels of AST, ALT and ALP in the blood were prevented by the metformin and ZnO-metformin nanocomposite against the action of CCl4, as well as liver damage associated with it. Furthermore, metformin or/and ZnO-metformin nanocomposite reversed the SOD, GPx and GR activity that was found to be lowered due to CCl4, as well as increased MDA levels under the same condition. The extent of hepatoprotection with respect to the two agents in question also differed significantly in terms of dose. The ZnO-metformin nanocomposite hepatoprotective effects occurred at lower doses than metformin. ZnO alone did not alter the CCl4-induced hepatic injury.

Conclusions

The ZnO-metformin nanocomposite was a more efficient hepatoprotective agent at lower doses than metformin. The ZnO-metformin nanocomposite has the potential to be a replacement for metformin as a hepatoprotective drug candidate.

Schlagwörter

metforminzno-metformin nanocompositeliver injurycarbon tetrachloride

Zitieren

APA

Adibipour, F., Salehirad, M., Hayes, A., Hekmati, M., & Motaghinejad, M. (2024). Preventive Effect of ZnO-Metformin Nanocomposite Against Carbon Tetrachloride-Induced Hepatotoxicity. Nanomedicine Research Journal, 9(2), 155-163. https://doi.org/10.22034/nmrj.2024.02.004

Vancouver

Adibipour F, Salehirad M, Hayes A, Hekmati M, Motaghinejad M. Preventive Effect of ZnO-Metformin Nanocomposite Against Carbon Tetrachloride-Induced Hepatotoxicity. Nanomedicine Research Journal. 2024;9(2):155-163. doi:10.22034/nmrj.2024.02.004

BibTeX
@article{Adibipour2024,
  author = {Adibipour, Fatemeh and Salehirad, Mahsa and Hayes, A.Wallace and Hekmati, Malak and Motaghinejad, Majid},
  title = {Preventive Effect of ZnO-Metformin Nanocomposite Against Carbon Tetrachloride-Induced Hepatotoxicity},
  journal = {Nanomedicine Research Journal},
  year = {2024},
  volume = {9},
  number = {2},
  pages = {155--163},
  doi = {10.22034/nmrj.2024.02.004}
}
Kostenlos starten →